• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Motif Bio plc - Articles and news items

First patient dosed in Phase 3 iclaprim ABSSSI trial

Industry news / 2 March 2016 / Victoria White

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections…

Motif Bio and Covance sign agreement to run Iclaprim Phase III trials

Industry news / 16 October 2015 / Victoria White

The trials will evaluate the efficacy and safety of intravenous iclaprim versus intravenous vancomycin in the treatment of acute bacterial skin and skin structure infections…

FDA grants Fast Track designation to iclaprim

Industry news / 3 September 2015 / Victoria White

The FDA has granted Fast Track designation to iclaprim to treat acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia…

FDA QIDP designation for Motif’s iclaprim for HABP

Industry news / 20 July 2015 / Victoria White

The US FDA has designated Motif Bio’s iclaprim as a Qualified Infectious Diseases Product (QIDP) for hospital acquired bacterial pneumonia (HABP)…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringFIND OUT MORE
+ +